Physician profile
Mohamed Dauda
NPI 1124210026
$2,832.70
in general payments reported to CMS, 2019-2025
23 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $66.48 · 2021: $138 · 2022: $267 · 2023: $673 · 2024: $531 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $739.54 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Neurocrine Biosciences, INC. | $551.89 | 2023-2025 | Ingrezza |
| Exact Sciences Corporation | $246.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $230.92 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $186.33 | 2023 | Inpefa |
| Dynavax Technologies Corporation | $162.55 | 2021-2022 | |
| Dexcom, INC. | $130.75 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $124.80 | 2024 | |
| Novartis Pharmaceuticals Corporation | $73.00 | 2019 | |
| Novo Nordisk INC | $60.47 | 2023-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $56.15 | 2019-2022 | |
| Pfizer INC. | $52.71 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $37.18 | 2019-2023 | Verquvo |
| Lilly USA, LLC | $27.15 | 2025 | Mounjaro, Zepbound |
| Medtronic Vascular, INC. | $25.03 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $19.30 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.51 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.86 | 2025 | Caplyta |
| Viiv Healthcare Company | $15.88 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.63 | 2023 | Strensiq |
| Medtronic, INC. | $14.33 | 2023 | Minimed 770g |
| Glaxosmithkline, LLC. | $13.73 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Dauda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.